Histotripsy clinical trial for kidney cancer treatment expanded in Hong Kong

According to a report by the South China Morning Post, the clinical trial of histotripsy technology for the treatment of kidney cancer has been expanded in Hong Kong. This innovative treatment method uses focused ultrasound to destroy tumours, which is completely non-invasive. The Li Ka Shing Foundation announced on Wednesday that three leading hospitals in the city—CUHK Medical Centre, Gleneagles Hospital Hong Kong, and Hong Kong Sanatorium & Hospital—will participate in this trial. A total of 30 patients will be treated under this test.

According to a statement from the Li Ka Shing Foundation, Hong Kong has become the first city in Asia to test the safety and effectiveness of treating kidney diseases through histotripsy. This project is part of business tycoon Li Ka-shing's biotech investments, which have garnered international attention. The objective of this technology is to make cancer treatment simpler and more effective.

Histotripsy is a sophisticated medical procedure that breaks down cancer tumours using ultrasound waves without surgery. This technology is primarily used to target and remove tumours.